AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24617228 — intervention group
Group type: COMPARATOR
Intervention: Regular perpendicular acupuncture (40 mm) at Guanyuan (CV 4)
Number of subjects: 132
Study 24617228 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-oblique acupuncture for postpartum urinary retention
Number of subjects: 132
Study 24617228 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-oblique acupuncture for prostate-induced urinary retention
Number of subjects: 132
Study 24617228 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-oblique acupuncture for orthopedic postoperative urinary retention
Number of subjects: 132
Study 24617228 — intervention group
Group type: COMPARATOR
Intervention: Regular perpendicular acupuncture for postpartum urinary retention
Number of subjects: 132
Study 24617228 — intervention group
Group type: COMPARATOR
Intervention: Regular perpendicular acupuncture for prostate-induced urinary retention
Number of subjects: 132
Study 24617228 — intervention group
Group type: COMPARATOR
Intervention: Regular perpendicular acupuncture for orthopedic postoperative urinary retention
Number of subjects: 132
Study 22000794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal anesthesia with 4 squirts of lidocaine spray
Number of subjects: 300
Study 22000794 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 300
Study 22000794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 18060565 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric ultrasonic device
Number of subjects: 14
Study 18060565 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetostrictive ultrasonic device
Number of subjects: 14
Study 18060565 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instrumentation
Number of subjects: 14
Study 18060565 — intervention group
Group type: COMPARATOR
Intervention: Untreated teeth (control)
Number of subjects: 14
Study 16563920 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) fenoldopam
Number of subjects: 33
Study 16563920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarenal (IR) fenoldopam
Number of subjects: 33
Study 16563920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarenal (IR) fenoldopam (2 hours after drug discontinuation)
Number of subjects: 33
Study 12062615 — intervention group
Group type: EXPERIMENTAL
Intervention: Two fractions of high-dose-rate brachytherapy (9 Gy per application, 1 week apart)
Number of subjects: 49
Study 12062615 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemotherapy (cisplatin 20 mg/m(2)/day for 5 days during EBRT)
Number of subjects: 49
Study 12062615 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 49
Study 12062615 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose to rectum from high-dose-rate brachytherapy
Number of subjects: 49
Study 12062615 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose to bladder from high-dose-rate brachytherapy
Number of subjects: 49
Study 12062615 — intervention group
Group type: EXPERIMENTAL
Intervention: Late toxicity
Number of subjects: 49
Study 10545574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup-feeding
Number of subjects: 98
Study 10545574 — intervention group
Group type: COMPARATOR
Intervention: Bottle-feeding
Number of subjects: 98
Study 10545574 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 98
Study 7581414 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfactory stable relationship
Number of subjects: 32
Study 7581414 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable relationship
Number of subjects: 32
Study 7581414 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher occupational social class
Number of subjects: 32
Study 7581414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulfilling social life and job
Number of subjects: 32
Study 2253662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 400 mg
Number of subjects: 80
Study 2253662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 400 mg t.d.s. for 5 to 10 days
Number of subjects: 80
Study 483202 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 15 mg/day
Number of subjects: 4
Study 483202 — intervention group
Group type: COMPARATOR
Intervention: Full medical treatment
Number of subjects: 4
Study 30043207 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF 100 µg/kg, single subcutaneous injection 72 hours after chemotherapy
Number of subjects: 0
Study 30043207 — intervention group
Group type: COMPARATOR
Intervention: rhG-CSF 5 µg/kg/day, subcutaneous injection once a day for 14 days or until ANC ≥ 10.0 × 10^9/l twice, starting 72 hours after chemotherapy
Number of subjects: 0
Study 27258925 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Parenting program
Number of subjects: 119
Study 27258925 — intervention group
Group type: COMPARATOR
Intervention: Parent talk (control)
Number of subjects: 119
Study 25437481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralase FS 60‐kHz femtosecond laser
Number of subjects: 60
Study 25437481 — intervention group
Group type: COMPARATOR
Intervention: Intralase iFS 150‐kHz femtosecond laser
Number of subjects: 60
Study 25437481 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 23748286 — intervention group
Group type: EXPERIMENTAL
Intervention: ICNSS for nursing workload estimation and nurse allocation
Number of subjects: 105
Study 23748286 — intervention group
Group type: COMPARATOR
Intervention: Equal distribution of sickbeds to nurses
Number of subjects: 105
Study 20005132 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-adapted HES 130/0.42
Number of subjects: 15
Study 20005132 — intervention group
Group type: COMPARATOR
Intervention: Nonplasma-adapted HES 130/0.42
Number of subjects: 15
Study 18467724 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation levels at MINT loci 2, 3, and 31
Number of subjects: 251
Study 18467724 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic subclassification based on MINT methylation data
Number of subjects: 251
Study 17409825 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (15 mg/m/day)
Number of subjects: 29
Study 17409825 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (6.5 mg/m/day)
Number of subjects: 29
Study 17409825 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (17 mg/m/day)
Number of subjects: 29
Study 17409825 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of paclitaxel with concurrent radiation therapy (RT)
Number of subjects: 29
Study 14635510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 300 mg/day and nicotine patches
Number of subjects: 88
Study 10516865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil in the late in-hospital phase of AMI without heart failure
Number of subjects: 0
Study 10516865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil in the late in-hospital phase of AMI with heart failure
Number of subjects: 0
Study 10516865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil combined with thrombolysis
Number of subjects: 0
Study 10516865 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 0
Study 10516865 — intervention group
Group type: COMPARATOR
Intervention: Intravenous verapamil in the early phase of AMI
Number of subjects: 0
Study 8730125 — intervention group
Group type: EXPERIMENTAL
Intervention: DISH patients
Number of subjects: 100
Study 8730125 — intervention group
Group type: COMPARATOR
Intervention: Control group (DISH-free patients)
Number of subjects: 100
Study 8730125 — intervention group
Group type: EXPERIMENTAL
Intervention: DISH patients with diabetes, dyslipidemia, or hyperuricemia
Number of subjects: 100
Study 8730125 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined metabolic features (DM+DL, DM+HU, DM+DL+HU)
Number of subjects: 100
Study 8730125 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 100
Study 1655136 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fraxiparine) 41 IU/kg/day for three days, then 62 IU/kg/day from day 4 to day 10
Number of subjects: 349
Study 1655136 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin at intervals of eight hours, doses adjusted to maintain activated thromboplastin time at two to five seconds above control values
Number of subjects: 349
Study 6128021 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (0.5-20 mg)
Number of subjects: 6
Study 6128021 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (27 ng/ml plasma concentration)
Number of subjects: 6
Study 6128021 — intervention group
Group type: COMPARATOR
Intervention: Timolol and placebo
Number of subjects: 6
Study 30852479 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone combined with bevacizumab
Number of subjects: 60
Study 30852479 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticancer drugs
Number of subjects: 60
Study 29767382 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraCal
Number of subjects: 46
Study 29767382 — intervention group
Group type: COMPARATOR
Intervention: MTA
Number of subjects: 46
Study 26587993 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (up to 4 g/d)
Number of subjects: 165
Study 26587993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 24583571 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/kg of hypertonic saline (HTS) over 1 hour
Number of subjects: 44
Study 24583571 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 44
Study 24583571 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/kg of hypertonic saline (HTS)
Number of subjects: 44
Study 24583571 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 44
Study 22345317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-called smokers who received telephone counseling
Number of subjects: 695
Study 22345317 — intervention group
Group type: COMPARATOR
Intervention: Quitline callers
Number of subjects: 695
Study 20965384 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk Score
Number of subjects: 296
Study 19076885 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized limonene
Number of subjects: 0
Study 19076885 — intervention group
Group type: EXPERIMENTAL
Intervention: Limonene-1-hydroperoxide
Number of subjects: 0
Study 19076885 — intervention group
Group type: COMPARATOR
Intervention: Pure limonene
Number of subjects: 0
Study 15903129 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine pretreatment (20 mg daily for 3 consecutive days)
Number of subjects: 16
Study 15903129 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine/tramadol combination
Number of subjects: 16
Study 15903129 — intervention group
Group type: COMPARATOR
Intervention: Placebo/tramadol
Number of subjects: 16
Study 15903129 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine in combination with placebo
Number of subjects: 16
Study 12812852 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy radiotherapy (RT)
Number of subjects: 234
Study 12812852 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy in five fractions of radiotherapy (RT)
Number of subjects: 234
Study 12812852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention arms (8 Gy and 20 Gy)
Number of subjects: 234
Study 10485389 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch test for wheat
Number of subjects: 39
Study 10485389 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test for wheat
Number of subjects: 39
Study 10485389 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP RAST (wheat-specific IgE measurement)
Number of subjects: 39
Study 10485389 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat challenge (double-blind, placebo-controlled or open)
Number of subjects: 39
Study 10485389 — intervention group
Group type: COMPARATOR
Intervention: Skin prick test
Number of subjects: 39
Study 10485389 — intervention group
Group type: COMPARATOR
Intervention: Patch test
Number of subjects: 39
Study 10485389 — intervention group
Group type: COMPARATOR
Intervention: CAP RAST
Number of subjects: 39
Study 8799415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 57
Study 8799415 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy (mitomycin C and doxorubicin)
Number of subjects: 57
Study 8799415 — intervention group
Group type: COMPARATOR
Intervention: No specific anti-cancer treatment
Number of subjects: 57
Study 1633433 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (Fidia, 300 mg/d)
Number of subjects: 33
Study 1633433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 6337787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil, 240 mg
Number of subjects: 52
Study 6337787 — intervention group
Group type: COMPARATOR
Intervention: Digoxin, 0.25 mg and 0.5 mg daily
Number of subjects: 52
Study 6337787 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin, 0.25 mg and verapamil
Number of subjects: 52
Study 6337787 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil alone
Number of subjects: 52
Study 30975352 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch group
Number of subjects: 67
Study 30975352 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 30278529 — intervention group
Group type: EXPERIMENTAL
Intervention: Yufeining (YFN) treatment
Number of subjects: 60
Study 30278529 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 27128664 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO mouth rinse (6.4% maltodextrin)
Number of subjects: 8
Study 25219857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans GBI‐30, 6086 (BC30)
Number of subjects: 0
Study 25219857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (FOS) and galactooligosaccharides (GOS)
Number of subjects: 0
Study 25219857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22205316 — intervention group
Group type: EXPERIMENTAL
Intervention: Gustatory stimuli (intensity and hedonics of 5 basic tastes and tastes and odors of foods and nonfoods)
Number of subjects: 30
Study 22205316 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor recognition
Number of subjects: 30
Study 22205316 — intervention group
Group type: EXPERIMENTAL
Intervention: Central auditory processing
Number of subjects: 30
Study 22205316 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral assessment of size and shape
Number of subjects: 30
Study 22205316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pain sensitivity
Number of subjects: 30
Study 22205316 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-image dissatisfaction
Number of subjects: 30
Study 20478383 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 1000 mg/day for 12 weeks
Number of subjects: 1002
Study 20478383 — intervention group
Group type: COMPARATOR
Intervention: Quercetin 500 mg/day for 12 weeks
Number of subjects: 1002
Study 20478383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study 18034195 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (short exposure, high-energy laser settings): exposure 0.02 s, 300 microm
Number of subjects: 20
Study 18034195 — intervention group
Group type: COMPARATOR
Intervention: Treatment A (conventional settings): exposure time 0.1 s, power sufficient to produce visible grey-white burns, spot size 300 microm
Number of subjects: 20
Study 15975490 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% MCT fat emulsion (PL:TG 0.06)
Number of subjects: 30
Study 15975490 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% MCT fat emulsion (PL:TG 0.06)
Number of subjects: 30
Study 15975490 — intervention group
Group type: COMPARATOR
Intervention: 10% MCT/LCT fat emulsion (PL:TG 0.12)
Number of subjects: 30
Study 12356202 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Extended Activities of Daily Living Scale (EADL)
Number of subjects: 240
Study 10520791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 1920
Study 10520791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1920
Study 7893502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoimmunological monitoring (CIM) after cryopreserved aortic valve implantation
Number of subjects: 16
Study 7893502 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-compatible allografts (group I, n = 9)
Number of subjects: 16
Study 7893502 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-incompatible allografts (group II, n = 7)
Number of subjects: 16
Study 7893502 — intervention group
Group type: COMPARATOR
Intervention: Control group (bioprosthetic valve replacement, n = 8)
Number of subjects: 16
Study 3162737 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment focusing on critical features of tooth anatomy and preparation methods
Number of subjects: 192
Study 3162737 — intervention group
Group type: COMPARATOR
Intervention: Control treatment with conventional written and oral descriptions
Number of subjects: 192
Study 29098908 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% topical spray
Number of subjects: 34
Study 29098908 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.05% topical spray
Number of subjects: 34
Study 29098908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle spray
Number of subjects: 34
Study 27167219 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks ribavirin mono-therapy prior to adding pegIFN-α
Number of subjects: 58
Study 27167219 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks ribavirin double dosing concomitant with pegIFN-α
Number of subjects: 58
Study 27167219 — intervention group
Group type: COMPARATOR
Intervention: standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α
Number of subjects: 58
Study 24480077 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day)
Number of subjects: 40
Study 22660371 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (arm restriction)
Number of subjects: 28
Study 22660371 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 28
Study 20156473 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual learning training (repeated measurements of visual-span profiles at 10 degrees below fixation, in four daily sessions)
Number of subjects: 18
Study 20156473 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 18
Study 18660549 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold respiratory-muscle training (RMT) for 8 weeks
Number of subjects: 26
Study 18660549 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group (CON)
Number of subjects: 26
Study 16206003 — intervention group
Group type: EXPERIMENTAL
Intervention: LPLC (7 mmHg)
Number of subjects: 50
Study 16206003 — intervention group
Group type: COMPARATOR
Intervention: HPLC (14 mmHg)
Number of subjects: 50
Study 16206003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 12427412 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated lower-limb training (3 months of low-level bicycle and treadmill exercise, minute ventilation <25 l/min)
Number of subjects: 17
Study 12427412 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated lower-limb training
Number of subjects: 17
Study 12427412 — intervention group
Group type: COMPARATOR
Intervention: Guided imagery relaxation techniques (active control)
Number of subjects: 17
Study 10355231 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked orthographic priming for word targets
Number of subjects: 0
Study 10355231 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked repetition priming for nonword targets
Number of subjects: 0
Study 10355231 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological primes
Number of subjects: 0
Study 10355231 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked primes
Number of subjects: 0
Study 8649684 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg vasopressin diluted with 20 mL saline
Number of subjects: 33
Study 8649684 — intervention group
Group type: COMPARATOR
Intervention: 1.5% glycine as the irrigating medium
Number of subjects: 33
Study 1998874 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid isotope scan
Number of subjects: 68
Study 1998874 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid ultrasound examination
Number of subjects: 68
Study 1998874 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid isotope scans and ultrasound
Number of subjects: 68
Study 6360739 — intervention group
Group type: EXPERIMENTAL
Intervention: Tromantadine hydrochloride (TH) ointment
Number of subjects: 20
Study 6360739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30612833 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (iNPWT)
Number of subjects: 398
Study 30612833 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 398
Study 27931259 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal veno-venous hemoperfusion therapy with the LPS Adsorber
Number of subjects: 32
Study 27931259 — intervention group
Group type: COMPARATOR
Intervention: Veno-venous hemoperfusion therapy with a placebo adsorber (without active LPS-binding peptide)
Number of subjects: 32
Study 25155070 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling prevention maintenance intervention (PMI) with brief telephone contacts every 8 weeks over 36 months
Number of subjects: 701
Study 25155070 — intervention group
Group type: COMPARATOR
Intervention: Time- and dose-consistent PMI focused on general health (comparison condition)
Number of subjects: 701
Study 21896539 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m² twice daily for 24 weeks)
Number of subjects: 1987
Study 21896539 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/FA (Mayo Clinic regimen)
Number of subjects: 1987
Study 19356752 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary gonadotropins
Number of subjects: 231
Study 19356752 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 231